Oxford Biomedica and Institut Merieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Merieux as part of pure-play CDMO transformation
Oxford - Oxford Biomedica plc , a quality and innovation-led cell and gene therapy CDMO, and Institut Merieux SA today announce that they have entered into exclusive negotiations with respect to the...
Source: marketscreener.com